Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom

Journal of Clinical Microbiology

Volumn 51, Issue 1, 2013, Pages 217-223

  Broda, Agnieszka ^a,b   Jebbari, Heather ^a   Beaton, Kate ^a   Mitchell, Sarah ^a   Drobniewski, Francis ^a,b  

^a HPA National Mycobacterium Reference Laboratory   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOXITIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; IMIPENEM; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CYSTIC FIBROSIS; DISK DIFFUSION; HUMAN; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; SPECIES COMPARISON; UNITED KINGDOM;

ANTI-INFECTIVE AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GREAT BRITAIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; UNITED STATES;

CORYNEBACTERINEAE; MYCOBACTERIUM ABSCESSUS;

EID: 84871694678     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02260-12     Document Type: Article

References (22)

1. Brown BA, Wallace RJ, Jr, Onyi GO, De Rosas V, Wallace RJ, III. 1992. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob. Agents Chemother. 36:180-184.
2. Brown-Elliott BA, Wallace RJ, Jr. 2002. Clinical and taxonomic status of pathogenic non pigmented or late pigmented rapidly growing mycobacteria. Clin. Microbiol. Rev. 15:716-746. (Pubitemid 41199631)
3. Esther C, Jr, Henry M, Molina P, Leigh M. 2005. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr. Pulmonol. 40:39-44. (Pubitemid 40917906)
4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Lademarco MF, Iseman M, Olivier K, Ruoss S, Fordham von Reyn C, Wallace RJ, Jr, Winthrop K. 2007. An official American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Thoracic Society, New York, NY.
5. Adékambi T, Berger P, Raoult D, Drancourt M. 2006. RpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int. J. Syst. Evol. Microbiol. 56:133-143. (Pubitemid 43125908)
6. Wong YL, Choo SW, Tan JL, Ong CS, Ng KP, Ngeow YF. 2012. Draft genome sequence of Mycobacterium bolletii strain M24, a rapidly growing mycobacterium of contentious taxonomic status. J. Bacteriol. 194:4475.
7. Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace RJ, Jr, Olivier KN, Holland SM, Sampaio EP. 2009. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J. Clin. Microbiol. 7:1985-1995.
8. Andrews JM, BSAC Working Party on Susceptibility Testing. 2007. BSAC standardized disc susceptibility testing method (version 6). J. Antimicrob. Chemother. 60:20-41. (Pubitemid 47073273)
9. Clinical and Laboratory Standards Institute. 2011. Document M100-S11. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement. CLSI, Wayne, PA.
10. Bastian S, Veziris N, Roux Brossier A-LF, Gaillard Jarlier J-LV, Cambau E. 2011. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob. Agents Chemother. 55:775-781.
11. Nash KA, Brown-Elliott BA, Wallace RJ, Jr. 2009. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 4:1367-1376.
12. National Committee for Clinical Laboratory Standards. 2003. Document M24-A. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS, Wayne, PA.
13. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. 2006. Technical note on tigecycline. Clin. Microbiol. Infect. 12:1147-1149.
14. Wallace RJ, Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. 2002. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46:3164-3167.
15. Swenson JM, Thornsberry C, Silcox VA. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:86-192.
16. Wood GL, Bergmann JS, Witebsky FG, Fahle GA, Wagner A, Boulet B, Plaunt M, Brown BA, Wallace RJ, Jr. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 6:1676-1682. (Pubitemid 29235205)
17. Huang TS, Lee SS, Hsueh PR, Tsai HC, Chen YS, Wann SR, Leu HS, Ko WC, Yan JJ, Yuan SZ, Chang FY, Lu JJ, Wang JH, Wang HK, Liu YC. 2008. Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002. J. Formos. Med. Assoc. 107:281-287. (Pubitemid 351663104)
18. Park S, Kim S, Park EM, Kim H, Kwon OJ, Chang CL, Lew WJ, Park YK, Koh WJ. 2008. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J. Korean Med. Sci. 23:49-52.
19. Swenson JM, Wallace RJ, Jr, Silcox VA, Thornsberry C. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 6:807-811. (Pubitemid 16196919)
20. Wallace RJ, Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. 2001. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother. 45:764-767. (Pubitemid 32182022)
21. Satyanarayana G, Heysel SK, Scully KW, Houpt ER. 2011. Mycobacterial infections in a large Virginia hospital, 2001-2009. BMC Infect. Dis. 5:113.
22. Clinical and Laboratory Standards Institute. 2010. Document M100-S10. Performance standards for amoxicillin and amoxicillin/clavulanic acid susceptibility testing. CLSI, Wayne, PA.